References
- Moghul S, Wilkinson D. Use of acetylcholinesterase inhibitors in Alzheimer’s disease. Expert Rev Neurotherapeutics 2001;1:61–9
- Farlow M, Anand R, Messina J, et al. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer’s disease. Eur Neurol 2000;44:236–41
- Raskind MA, Peskind ER, Wessel T, et al. Galantamine in AD. A 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 2000;54: 2261–8
- Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001;57:489–95
- Waldemar G, Dubois B, Emre M, et al. Diagnosis and management of Alzheimer’s disease and other disorders associated with dementia. The role of neurologists in Europe. Eur J Neurol 2000;7:133–44
- Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1154–66
- NICE (National Institute of Clinical Excellence). Guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer’s disease [online]. Available from http:// www.nice.org.uk [accessed 2001]
- Kumar V, Anand R, Messina J, et al. An efficacy and safety analysis of Exelon® in Alzheimer’s disease patients with concurrent vascular risk factors. Eur J Neurol 2000;7:159–69
- Moretti R, Torre P, Antonello RM, Cazzato G. Rivastigmine in subcortical vascular dementia: an open 22-month study. J Neurol Sci 2002;203–204:141–6
- Erkinjuntti T, Kurz A, Gauthier S, et al. Efficacy of galantamine in probable vascular dementia and Alzheimer’s disease combined with cerebrovascular disease: a randomised trial. Lancet 2002;359:1283–90
- Black S, Román G, Geldmacher DS, et al. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 2003;34:2323–32
- McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer’s disease. Report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology 1984;34:939–44
- Román GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDSAIREN International Workshop. Neurology 1993;43:250–60
- Folstein M, Folstein S, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–98
- McLendon BM, Doraiswamy PM. Defining meaningful change in Alzheimer’s disease trials: the donepezil experience. J Geriatr Psychiatry Neurol 1999;12:39–48
- Burback D, Molnar FJ, St John P, Man-Son-Hing M. Key methodological features of randomized controlled trials of Alzheimer’s disease therapy: minimal clinically important difference, sample size and trial design. Dementia Geriatr Cogn Disord 1999; 10:534–40
- Giacobini E. Cholinesterase inhibitor therapy stabilizes symptoms of Alzheimer’s disease. Alzheimer Dis Assoc Disord 2000; 14:S3–S10
- Lanctôt KL, Hermann N, Yau KK, et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer’s disease: a meta-analysis. Can Med Assoc J 2003;169:557–64
- Giacobini E. Cholinesterase inhibitors: from the Calabar bean to Alzheimer therapy. In: Cholinesterases and cholinesterase inhibitors. London: Martin Dunitz Ltd; 2000. p. 181–226
- Arias E, Alés E, Gabilan NH, et al. Galantamine prevents apoptosis induced by β-amyloid and thapsigargin: involvement of nicotinic acetylcholine receptors. Neuropharmacology 2004;46:103–14
- Doody RS, Geldmacher DS, Gordon B, et al. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer’s disease. Arch Neurol 2001;58:427–33